Nasdaq Stockholm

XSpray Pharma AB (publ)

ISIN SE0009973563Filings at the FI

At a glance

Most recent filing on September 29, 2026 — an open-market purchase by Blake Leitch on Sep 28, 2026.

We hold 92 visible filings, going back to September 26, 2017.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 92 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 92. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Blake Leitch Closely associated: Chief executive officer
475,337 SEKOpen-market buy
TradedSep 28, 2026FiledSep 29, 2026
Anders Bladh Closely associated: Board member
38,745 SEKOpen-market buy
TradedAug 20, 2026FiledAug 20, 2026
Curt Mikael von Euler-Chelpin Other member of the administrative, management or supervisory body
48,300 SEKOpen-market buy
TradedJun 18, 2026FiledJun 20, 2026
Blake Leitch Chief executive officer
664,977 SEKOpen-market buy
TradedJun 12, 2026FiledJun 15, 2026
Blake Leitch Chief executive officer
76,628 SEKOpen-market buy
TradedJun 15, 2026FiledJun 15, 2026